

1 Mid-Regional pro-Adrenomedullin (MR-proADM), C-Reactive Protein (CRP) 2 and Other Biomarkers in the Early Identification of Disease Progression in 3 COVID-19 Patients in the Acute NHS Setting

4
5 Nathan Moore^{1#*}, Rebecca Williams^{1#}, Matilde Mori², Beatrice Bertolusso¹, Gabrielle Vernet¹, Jessica Lynch¹,
6 Peter Philipson³, Thomas Ledgerwood¹, Stephen P. Kidd¹, Claire Thomas¹, Veronica Garcia-Arias¹, Michelle
7 Young⁴, Kordo Saeed^{2,5}, Kirsty Gordon¹, Nicholas Cortes^{1,2,6,7}

8
9 ¹Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital, Basingstoke, UK

10 ²University of Southampton, School of Medicine, UK

11 ³Newcastle University, School of Mathematics, Statistics & Physics, UK

12 ⁴Whittington Hospital, London, UK

13 ⁵University Hospital Southampton NHS Foundation Trust, Southampton, UK

14 ⁶Gibraltar Health Authority, Gibraltar, UK

15 ⁷University of Gibraltar, Gibraltar, UK

16
17
18 #Joint first authors

19 *Corresponding author:

20 Nathan.Moore@hhft.nhs.uk

21 01256 473202

22
23 Keywords: MR-proADM, SARS-CoV-2, COVID-19, Mortality, Biomarkers, Emergency Department, Disease
24 progression

25
26
27 Aims: There is a lack of biomarkers validated for assessing clinical deterioration in COVID-19 patients upon
28 presentation to secondary or tertiary care. This evaluation looked at the potential clinical application of C-
29 Reactive Protein, Procalcitonin, Mid-Regional pro-adrenomedullin (MR-proADM) and White Cell Count to
30 support prediction of clinical outcomes.

31
32 Methods: 135 patients presenting to Hampshire Hospitals NHS Foundation Trust between April and June 2020
33 confirmed to have COVID-19 via RT-qPCR were included. Biomarkers from within 24 hours of admission were
34 used to predict disease progression by Cox regression and area under the receiver operating characteristic
35 (AUROC) curves. The endpoints assessed were 30-day all-cause mortality, intubation and ventilation, critical
36 care admission and non-invasive ventilation (NIV) use.

37
38 Results: Elevated MR-proADM was shown to have the greatest ability to predict 30-day mortality adjusting for
39 age, cardiovascular, renal and neurological disease. A significant association was also noted between raised
40 MR-proADM and CRP concentrations and the requirement for critical care admission and non-invasive
41 ventilation.

42
43 Conclusions: The measurement of MR-proADM and CRP in patients with confirmed COVID-19 infection upon
44 admission shows significant potential to support clinicians in identifying those at increased risk of disease
45 progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions.

46
47
48

49 Introduction

50

51 Since initial reports of a cluster of pneumonia cases arising from Wuhan, Hubei and the subsequent
52 identification of the causative *betacoronavirus*, the severe acute respiratory syndrome coronavirus 2 (SARS-
53 CoV-2) has infected over 100 million people globally and directly resulted in the deaths of approximately 2·3
54 million by January 2021.

55

56 The progressive multi-organ failure associated with SARS-CoV-2 mortality is driven in part by significant
57 inflammation and microvascular thrombosis. Presence of SARS-CoV-2 within the endothelium can cause a
58 secondary endotheilitis and an impairment of vascular blood flow, a pro-thrombotic state and vascular leakage.¹
59 During endotheilitis there is elevation of biomarkers, such as neutrophil extracellular traps, that can lead to
60 microvascular thrombosis and inflammation.²

61

62 Adrenomedullin is a peptide that has been shown to have a role in preserving the integrity and stability of the
63 endothelium after severe infection. Furthermore, it has potent vasodilatory properties, as well as having a role in
64 immunomodulation and metabolic regulation. It is upregulated in several pathogenic processes, including sepsis
65 and the progression of septic patients towards multi-organ failure.³⁻⁵

66

67 The novel biomarkers mid-regional proadrenomedullin (MR-proADM) has also been shown to be predictive of
68 poor clinical outcomes in patients with sepsis and infections involving the respiratory^{6,7} and urinary^{8,9} systems.
69 Similarly, it has been demonstrated during non-infective processes such as heart failure and kidney injury.¹⁰ As
70 a precursor amino acid sequence that splits from proadrenomedullin, MR-proADM is used as a surrogate marker
71 for adrenomedullin. It can be measured via an automated immunofluorescent assay, as levels are directly
72 proportional to adrenomedullin which rapidly breaks down in blood.

73

74 The instigation of an appropriate management plan is dependent on an adequate assessment of the infection
75 severity, which is determined by the host pathophysiological response and the virulence of the organism causing
76 infection.

77 However, infection is a dynamic process with infection severity changing over time within an individual. As
78 infection progresses, patients may transition from low severity to high severity which if not identified, may lead
79 to delayed or inappropriate therapy.

80 Therefore, biomarkers that could help stratify risk of disease progression are of clinical interest as they may help
81 guide appropriate early management and patient placement within hospital. A recent study by Saeed *et al.* found
82 that the measurement of MR-proADM could effectively predict disease progression; identifying those at
83 increased risk of mortality, those who would need ICU admission and those requiring a longer length of stay in
84 hospital. Furthermore, they identified its potential use in facilitating early discharge from hospital, with no
85 increase in mortality.¹¹

86

87 The aim of this study was to assess the effectiveness of a number of biomarkers, both established and emerging,
88 in the acute setting as prognostic markers to support clinicians in the early identification of patients with Covid-
89 19 at risk of mortality, ICU admission and ventilation.

90

91

92

93

94

95 Methods

96

97 Study Design and Data Collection

98

99 In this observational study, we identified patients confirmed to have SARS-CoV-2 at a district general hospital,
100 Hampshire Hospitals NHS Foundation Trust, during the first wave of the virus between April and June 2020.
101 SARS-CoV-2 was detected by real-time reverse-transcription PCR (rRT-PCR) using the COVID-19 genesig®
102 Real-Time PCR assay (Primerdesign Ltd, Chandler's Ford, UK). This resulted in 135 eligible consecutive
103 patients. All blood samples analysed were collected as part of routine clinical care on admission to hospital.
104 Measurement of C-reactive protein (CRP) on serum samples was performed on ADVIA 2400 analysers;
105 procalcitonin (PCT) on Centaur XP analysers and full blood count (FBC) and differential white blood cell
106 counts were performed on Ethylenediaminetetraacetic acid (EDTA) samples on Siemens Advia 2120i (all
107 Siemens Healthineers, Tarrytown, New York, USA). Measurement of MR-proADM was performed (within
108 72hours of collection, in line with manufacturer's guidance) on EDTA blood samples taken on admission using

109 an immunoassay (B.R.A.H.M.S. KRYPTOR™, Thermo Fisher Scientific, Henningsdorf, Germany). Those
110 performing the assays were blinded to clinical outcomes. Where these variables had not been requested by the
111 responsible clinician attempts were made to locate the original sample and perform the assay, within twenty-
112 four hours.

113
114 Patients were followed up until discharge, with demographics, comorbidities, admission and discharge dates,
115 non-invasive ventilation (NIV) use, need for intubation and ventilation, admission to ICU and mortality data
116 being anonymously collected. Clinicians caring for the patients were unaware that outcome data was being
117 collated in relation to the above biomarkers.

118 119 **Statistical Analysis**

120 Cases and controls were determined by outcome variables during univariate and multivariate Cox Regression.
121 However, this was only performed for clinical outcomes with a sufficiently high event per variable ratio.^{12,13}
122 Time to event analysis was right-censored at 30 days. The Cox proportional hazard models were checked for
123 proportionality by correlating sets of scaled Schoenfeld residuals with time, to test for independence between
124 residuals and time. Where proportionality was not met stratification was performed as necessary. Hazard ratios
125 and C-index score were calculated with corresponding 95% confidence intervals. Confounding variables for the
126 multivariate analysis were selected based on those that were significant upon univariate logistic regression
127 following Bonferroni correction, with a p-value of <0.005.

128
129 Symmetrically distributed variables were reported using the mean (standard deviation), whereas variables
130 exhibiting a skewed distribution were reported using the median [first quartile – third quartile]. The Chi-square
131 test (χ^2) was used to assess differences in categorical variables in the demographics and clinical characteristics
132 between those who did and did not die within 30 days, with the Mann-Whitney U test being used to assess
133 differences in continuous variables and Student's T-test for age.

134
135 Data analysis was performed using R version 4.0.1.

136
137 Receiver operating characteristic (ROC) curves with area under the curve (AUC) analysis was used to determine
138 predictive value for each clinical endpoint with 95% confidence intervals to establish significance. To
139 investigate if individual biomarkers offer a significant improvement in predicting an adverse outcome over a
140 model incorporating previously identified confounding variables, as outlined above, AUC analyses were
141 compared using a bootstrap method.

142 143 **Results**

144 Samples from 135 patients in total were analysed with a mean age of 64.6 years and a predominance of males
145 (51.9% male vs 48.1% female). The patient group included 105 who had survived by thirty days post admission
146 and 30 who had died by this timepoint. The characteristics of the patient cohort are described in Supplementary
147 Table 1.

148
149 Median biomarker concentrations in this group showed elevated median CRP 59mg/L (Q1-Q3 range 17 – 143)
150 and MR-proADM 1.02 nmol/L (Q1-Q3 range 0.71 - 1.61); median levels within normal clinical ranges for total
151 white blood cell count $7.1 \times 10^9/L$ (Q1-Q3 range 5.2 – 9.65), neutrophils $5.31 \times 10^9/L$ (Q1-Q3 range 3.51 – 7.66)
152 and PCT 0.13ng/mL (Q1-Q3 range 0.07 - 0.41) but a suppressed median lymphocyte count $0.98 \times 10^9/L$ (Q1-Q3
153 range 0.70 – 1.36).

154
155 Twenty-five of these patients were enrolled into the RECOVERY trial with 9 receiving standard care, 6 received
156 hydroxychloroquine, 6 received Lopinavir-Ritonavir and 3 received Azithromycin, all of which were deemed to
157 have no clinical benefit.¹⁴⁻¹⁶ One patient received dexamethasone as part of the RECOVERY trial. Otherwise,
158 none of the patients received other immunomodulation, including IL-6 inhibitors (tocilizumab or sarilumab), IL-
159 1 inhibitors (such as anakinra) or convalescent plasma.

160 Multivariate Cox regression adjusted for age, cardiovascular disease, renal disease and neurological disease.
161 Proportionality was checked for all Cox regression models and stratification performed as necessary.

162 163 **MR-proADM**

164 For this novel biomarker Saeed et al¹¹ have previously derived and proposed, in a non-COVID-19 acute patient
165 population, a cut-off of 1.54 nmol/L as a predictor of elevated mortality, higher rate of ICU admission and
166 longer length of stay. Applying this cut-off to our COVID-19 patient population shows significantly ($p =$
167 1.59×10^{-5}) lower mortality rate of 11.11% (N=11) in the patients with MR-proADM values < 1.54 nmol/L
168 (N=99 (73.33%)) compared to a higher mortality rate of 52.78% (N=19) in patients (N=36, (26.67%)) with

169 MR-proADM values equal to or exceeding a cut-off of 1.54 nmol/L. None of the patients who died (N=30) had
170 a MR-proADM value below the pre-defined threshold of < 0.88 nmol/L ($p = 1.61 \times 10^{-9}$), previously proposed in
171 a non-COVID-19 population by Saeed et al¹¹ as a potential cut-off for identifying patients at very low risk for
172 deterioration and no mortality.

173 Of interest, fifty-two (38.52%) patients with MR-proADM values of <0.88 nmol/L had a median inpatient stay
174 of 4 days (interquartile range [IQR] 0.75 – 9 days), representing a significantly shorter length of stay than those
175 with an MR-proADM of >0.88 nmol/L whose median stay was 12 days (IQR 5 – 22.5 days), $p < 0.00001$.

176

177 **30 Day Mortality**

178 Supplementary Table 1 compares the patient demographics and clinical characteristics between survivors and
179 non-survivors. Of note CRP, PCT and MR-proADM were all significantly raised amongst those that did not
180 survive at day 30.

181

182 Univariate Cox regression analysis found MR-proADM to have the greatest ability to predict 30 day mortality
183 (Wald 20.3, HR 1.5455 [1.279-1.868]), with CRP also proving effective at predicting 30 day mortality (Wald
184 4.02, HR 1.0034 [1.000-1.007]) as shown in Table 2.

185

186 Although PCT was significant for univariate Cox regression analysis (Wald 11.54, HR 1.0898 [1.037-1.145]),
187 the assumption of proportional hazards was not supported for PCT. Rather than attempting to estimate a time-
188 dependent coefficient in order to include covariates with time-varying coefficients multivariate analysis was not
189 performed. Both MR-proADM (Wald 23.735, HR 1.809[1.454-2.407]) and CRP (Wald 12.166, HR
190 1.0069[1.003-1.011]) remained significant for predicting 30 day mortality following adjustment for age,
191 cardiovascular disease, renal disease and neurological disease (Table 3). Similarly, lymphocyte count was
192 significant in predicting 30 day mortality after adjusting for co-variables (Wald 6.6564, HR 1.1213[1.028-
193 1.223]).

194

195 MR-proADM offered a significant improvement in predicting 30 day mortality over a model combining age,
196 renal disease, cardiovascular disease and neurological disease with an AUC of 0.874 ($p=0.01727$), whereas
197 CRP did not offer an improvement ($p=0.1464$).

198

199 **Intubation and Ventilation**

200 Elevated MR-proADM (Wald 12.37, HR 1.6015[1.232-2.082]) and CRP (Wald 16.57, HR 1.0069 [1.004-
201 1.010]) were both associated with an increase in the need for intubation and ventilation when performing
202 univariate cox regression. No firm conclusions are offered here from a multivariate analysis for prediction of
203 need for intubation and ventilation due to the lower number of events per predictor variable, though the results
204 are suggestive for both MR-proADM and CRP having efficacy in predicting the need for intubation.

205

206 **Admission to Critical Care**

207 On univariate analysis only CRP demonstrated a significant association with a requirement for admission to
208 critical care (Wald 15.83, HR [1.0055-1.008]), which was maintained once controlled for covariates, however
209 proportionality was affected by renal disease (Chisq 4.2243, $p=0.04$), which was therefore taken out by
210 stratification (Wald 22.062, HR 1.0078[1.005-1.011]). Although insignificant on univariate analysis MR-
211 proADM (Wald 3.2, HR 1.257[0.978-1.615]) did exhibit a significant association with a requirement for critical
212 care once covariates were controlled for (Wald 10.151, HR 1.5451 [1.182-2.019]).

213

214 Only CRP provided an improvement over the previously described combined model with an AUC of 0.8026
215 ($p=0.012$).

216

217 **Non-Invasive Ventilation**

218 Once again elevated CRP (Wald 15.53, HR 1.0061[1.003-1.009]) and MR-proADM (Wald 11.62, HR
219 1.4992[1.188-1.892]) were associated with requirement for NIV following univariate analysis, with both CRP
220 (Wald 18.293 HR 1.0081[1.004-1.012]) and MR-proADM (Wald 30.393, HR 2.5230[1.816-3.506]) both
221 retaining significance on multivariate analysis. Lymphocyte count was not a constant hazard and so further
222 analysis was omitted rather than estimating a time-dependent coefficient.

223

224 Both CRP and MR-proADM offered an improvement over the combined model with AUCs of 0.8544
225 ($p=0.000375$) and 0.8139 ($p=0.001052$) respectively.

226

227

228 **Table 1.** Univariate Cox regression for prediction of 30-day mortality, requirement of critical care, NIV and
 229 intubation and ventilation using biomarkers in baseline bloods
 230

Biomarker	Patients (N)	Cases (N)	Wald	D.F.	C-index [95% CI]	HR [95% CI]	p-value
Prediction of 30-day mortality							
MR-proADM	135	30	20.3	1	0.811 [0.746-0.876]	1.5455 [1.279-1.868]	6.64e-6
CRP ¹	135	30	4.02	1	0.613 [0.515-0.711]	1.0034 [1.000-1.007]	0.0449
PCT ²	116	26	11.54	1	0.621 [0.511-0.731]	1.0898 [1.037-1.145]	0.000681
Neutrophils	135	30	0.73	1	0.549 [0.445-0.653]	0.9555 [0.861-1.061]	0.394
Lymphocytes	135	30	3.53	1	0.448 [0.338-0.558]	1.0920 [0.996-1.197]	0.0603
Prediction of requiring critical care admission							
MR-proADM	135	31	3.2	1	0.614 [0.518-0.710]	1.2570 [0.978-1.615]	0.0737
CRP ¹	135	31	15.83	1	0.716 [0.624-0.808]	1.0055 [1.003-1.008]	0.0000695
PCT ²	116	31	0.03	1	0.687 [0.595-0.779]	1.0050 [0.951-1.062]	0.86
Neutrophils	135	31	0.37	1	0.609 [0.511-0.707]	1.0183 [0.960-1.080]	0.544
Lymphocytes	135	31	2.52	1	0.465 [0.357-0.573]	1.0759 [0.983-1.178]	0.113
Prediction of requiring NIV							
MR-proADM	135	23	11.62	1	0.726 [0.634-0.818]	1.4992 [1.188-1.892]	0.000651
CRP ¹	135	23	15.53	1	0.725 [0.617-0.833]	1.0061 [1.003-1.009]	0.0000813
PCT ²	116	22	0.1	1	0.772 [0.682-0.862]	1.0098 [0.952-1.072]	0.747
Neutrophils	135	23	0.06	1	0.432 [0.324-0.540]	0.9883 [0.901-1.085]	0.804
Lymphocytes	135	23	4.81	1	0.552 [0.442-0.662]	1.0991 [1.010-1.196]	0.0283
Prediction of intubation and ventilation							
MR-proADM	135	16	12.37	1	0.748 [0.650-0.846]	1.6015 [1.232-2.082]	0.000435
CRP ¹	135	16	16.57	1	0.745 [0.614-0.876]	1.0069 [1.004-1.010]	0.0000469
PCT ²	116	16	0.63	1	0.836 [0.746-0.926]	1.0215 [0.969-1.077]	0.429
Neutrophils	135	16	0.43	1	0.641 [0.514-0.768]	1.0259 [0.950-1.107]	0.513
Lymphocytes	135	16	0.09	1	0.468 [0.337-0.599]	0.9415 [0.630-1.408]	0.769

231 **Table 2.** Multivariate Cox regression for prediction of 30-day mortality, requirement of critical care, NIV and
 232 intubation and ventilation using biomarkers in baseline bloods
 233
 234

Biomarker	Patients (N)	Cases (N)	Wald	D.F.	C-index [95% CI]	HR [95% CI]	p-value
Prediction of 30-day mortality							
MR-proADM	135	30	23.736	5	0.827 [0.756-0.898]	1.8709 [1.454-2.407]	1.1e-6
CRP ¹	135	30	12.166	5	0.788 [0.704-0.872]	1.0069 [1.003-1.011]	0.000487
PCT	116	26	-	-	-	-	-
Neutrophils	135	30	0.9235	5	0.808 [0.745-0.871]	0.9445 [0.841-1.061]	0.336303
Lymphocytes	135	30	6.6564	5	0.791 [0.713-0.869]	1.1213 [1.028-1.223]	0.009879
Prediction of requiring critical care admission							
MR-proADM	135	31	10.151	5	0.713 [0.621-0.805]	1.5451 [1.182-2.019]	0.00144
CRP ¹	135	31	22.062	4	0.775 [0.702-0.848]	1.0078 [1.005-1.011]	2.64e-6
PCT ²	116	31	0.6084	5	0.715 [0.631-0.799]	1.0254 [0.963-1.092]	0.43564
Neutrophils	135	31	0.5761	5	0.686 [0.596-0.776]	1.0221 [0.966-1.081]	0.44772
Lymphocytes	135	31	1.4066	5	0.689 [0.599-0.779]	1.0638 [0.961-1.178]	0.23544
Prediction of requiring NIV							
MR-proADM	135	23	30.393	5	0.828 [0.740-0.916]	2.5230 [1.816-3.506]	3.53e-8
CRP ¹	135	23	18.293	5	0.799 [0.725-0.873]	1.0081 [1.004-1.012]	1.89e-5
PCT ²	116	22	1.39	5	0.755 [0.659-0.851]	1.0454 [0.971-1.125]	0.2383
Neutrophils	135	23	0.0266	5	0.72 [0.616-0.824]	0.9923 [0.905-1.089]	0.8706
Lymphocytes	135	23	-	-	-	-	-
Prediction of intubation and ventilation							
MR-proADM	135	16	22.648	5	0.793 [0.687-0.899]	2.2457 [1.609-3.134]	1.94e-6
CRP ¹	135	16	18.318	5	0.803 [0.713-0.893]	1.0088 [1.005-1.013]	1.87e-5
PCT ²	116	16	2.241	5	0.715 [0.617-0.813]	1.0558 [0.983-1.134]	0.134
Neutrophils	135	16	0.4543	5	0.665 [0.563-0.767]	1.0254 [0.953-1.103]	0.500
Lymphocytes	135	16	0.2663	5	0.67 [0.554-0.786]	0.8260 [0.400-1.707]	0.606

235 ¹ C-reactive protein
 236 ² Procalcitonin
 237
 238
 239
 240

241

242 **Table 3.** Univariate area under receiver operating characteristic curve data for predicting various outcomes from
243 baseline bloods

Biomarker	Patients (N)	Cases (N)	D.F.	AUC [95% CI]
30 day mortality				
MR-proADM	135	30	1	0.8441 [0.7761-0.9122]
CRP ¹	135	30	1	0.6132 [0.5066-0.7198]
PCT ²	116	26	1	0.6212 [0.4963-0.7460]
Neutrophils	135	30	1	0.5503 [0.4356-0.6650]
Lymphocytes	135	30	1	0.5629 [0.4373-0.6884]
Critical Care Admission				
MR-proADM	135	31	1	0.594 [0.4873-0.7007]
CRP ¹	135	31	1	0.7238 [0.6213-0.8263]
PCT ²	116	31	1	0.6856 [0.5771-0.7941]
Neutrophils	135	31	1	0.6158 [0.5104-0.7213]
Lymphocytes	135	31	1	0.5296 [0.4147-0.6446]
NIV				
MR-proADM	135	23	1	0.7189 [0.617-0.8209]
CRP ¹	135	23	1	0.722 [0.6068-0.8373]
PCT ²	116	22	1	0.7706 [0.6734-0.8677]
Neutrophils	135	23	1	0.5615 [0.4505-0.6726]
Lymphocytes	135	23	1	0.5646 [0.4476-0.6817]
Intubation and Ventilation				
MR-proADM	135	16	1	0.75 [0.6434-0.8566]
CRP ¹	135	16	1	0.7545 [0.6059-0.903]
PCT ²	116	16	1	0.8497 [0.7565-0.9429]
Neutrophils	135	16	1	0.6476 [0.5104-0.7848]
Lymphocytes	135	16	1	0.468 [0.324-0.612]

244

245

246 **Table 4.** Multivariate area under receiver operating characteristic data for predicting various outcomes from
247 baseline bloods

Biomarker	Patients (N)	Cases (N)	D.F.	AUC [95% CI]	Bootstrap
30 day mortality					
MR-proADM	135	30	5	0.874 [0.8085-0.9395]	0.01727
CRP ¹	135	30	5	0.8441 [0.769-0.9192]	0.1464
PCT ²	116	26	5	0.8406 [0.7619-0.9193]	0.06908
Neutrophils	135	30	5	0.8394 [0.7667-0.9121]	0.1417
Lymphocytes	135	30	5	0.8448 [0.7716-0.918]	0.1056
Critical Care Admission					
MR-proADM	135	31	5	0.7466 [0.6553-0.8379]	0.1457
CRP ¹	135	31	5	0.8026 [0.7256-0.8796]	0.012
PCT ²	116	31	5	0.7632 [0.6747-0.8517]	0.1465
Neutrophils	135	31	5	0.7252 [0.6359-0.8145]	0.2458
Lymphocytes	135	31	5	0.7317 [0.6413-0.8221]	0.2132
NIV					
MR-proADM	135	23	5	0.8544 [0.7727-0.9362]	0.000375
CRP ¹	135	23	5	0.8139 [0.7374-0.8904]	0.001052
PCT ²	116	22	5	0.7872 [0.6884-0.8861]	0.03331
Neutrophils	135	23	5	0.7418 [0.6341-0.8496]	0.07907
Lymphocytes	135	23	5	0.7519 [0.6461-0.8578]	0.05353
Intubation and Ventilation					
MR-proADM	135	16	5	0.812 [0.7071-0.9169]	0.005858
CRP ¹	135	16	5	0.8183 [0.7176-0.9189]	0.002934
PCT ²	116	16	5	0.7256 [0.6193-0.8319]	0.1324
Neutrophils	135	16	5	0.6817 [0.576-0.7874]	0.2557
Lymphocytes	135	16	5	0.6838 [0.5664-0.8012]	0.2675

248

249 Discussion

250 Our study demonstrates that use of biomarkers, both established and novel, has significant potential to support
251 clinical decisions and aid in identification of COVID-19 patients at both high and low risk for disease
252 progression. Of the biomarkers evaluated, elevated MR-proADM and CRP concentrations showed the greatest
253 potential for clinical application for utilisation to aid prediction of 30-day mortality, critical care admission
254 requirement and need for both invasive and non-invasive ventilation.

255

256 Of these, on multivariate regression analysis MR-proADM concentration showed the strongest association with
257 an increased 30-day mortality, requirement for non-invasive and invasive ventilation, with CRP showing the
258 strongest association with critical care admission. Our data are also suggestive of an association between
259 elevated MR-proADM and CRP concentration with a progression to being intubated and ventilated, though
260 more cases are required to verify this by controlling for covariates. This is consistent with previous studies that
261 have shown increased MR-proADM levels to be predictive of intensive care requirement in septic patients.¹⁷
262 Gonzalez del Castillo *et al.* identified MR-proADM to have the strongest association for ICU admission and

263 mortality compared to other blood biomarkers in bacterial infections; with concentrations of >1.77nmol/L
264 having significantly higher rates of ICU stay (8.1% vs 1.6%; p<0.001) and disease progression (29.7% vs
265 4.9%; p<0.001) compared to low MR-proADM concentrations.¹⁸ Application of these and our own findings,
266 applying previously derived thresholds of 0.88 and 1.54nmol/L may support clinicians with decisions regarding
267 earlier transfer of selected patients to wards with staff with experience in non-invasive ventilation, earlier
268 transfer to critical care and dependent on emerging trial data, potentially those who are at low risk of
269 deterioration suitable for ambulant monitoring. Similarly, subject to future studies, biomarker concentrations
270 may have significant value in signalling patients suitable for earlier commencement of targeted therapies,
271 including antiviral treatments (e.g. remdesivir) or immunomodulation with high dose steroids or interleukin-6
272 inhibitors (e.g. tocilizumab & sarilumab); in the NHS the latter are subject in the UK to specific inclusion
273 criteria which includes physiological derangement and requirement for respiratory support.^{19,20}
274

275 Previous studies examining the clinical utility of MR-proADM have focussed on predicting adverse events,
276 primarily in patients with a diagnosis of community-acquired pneumonia and elevated MR-proADM levels,⁴
277 reflecting the development of organ dysfunction. However, these patients typically have had low rates of severe
278 viral infection.^{11, 21} We have shown commensurate results in individuals diagnosed with SARS-CoV-2
279 infections. This may be explained by the development of endothelial dysfunction during SARS-CoV-2 infection,
280 for which endorecticular stress and the activation of the unfolded protein response is a significant inducer.
281 Endothelial dysfunction is associated with complications of Covid-19 including ARDS, thromboembolism and
282 vascular disease, with Adrenomedullin known to be a regulator of vascular tone and the integrity and stability of
283 the endothelial barrier.
284

285 The early recognition of potential for deterioration in patients infected with SARS-CoV-2 is invariably
286 challenging given the varied clinical course of the disease; particularly with the currently unpredictable potential
287 for deterioration during the second and third weeks of disease. As such, a reliable indicator for early
288 identification of patients at risk of deterioration or a more severe illness trajectory could be of great value, in
289 allowing for earlier targeted intervention or escalation of treatment.
290

291 The study has several limitations. Primarily, a higher event per variable ratio is desirable, fortunately however
292 stratification was only needed for one covariate. Greater power could be achieved through higher participant
293 numbers or through examining serial results over time. A multi-centre study with more patients could also allow
294 for prediction of progression from NIV to intubation. It is a retrospective study; it remains to be seen whether
295 application of such biomarkers into clinical diagnostic and management pathways will deliver the potential
296 expected benefits. Clinician confidence in use of such biomarkers to support decisions has to be developed and
297 evidenced in clinical practice.
298

299 MR-proADM and CRP may have other clinical utility worth exploring, such as whether measurement of these
300 has use in facilitating earlier discharges¹¹ in individuals with low concentrations or whether a delta change in
301 concentrations could be used to guide decisions on weaning ventilatory support and also the de-escalation or
302 stopping of antibiotics to mitigate against potential future antimicrobial resistance.
303

305 **Conclusions**

306 Biomarker measurement, in particular MR-proADM, in patients infected with SARS-CoV-2 upon presentation
307 to secondary care shows significant promise in allowing early identification of those at increased risk of disease
308 progression and mortality, possibly providing a tool to support clinical decisions regarding therapeutic
309 interventions and level of care setting. Additionally, adopting use of biomarkers such as MR-proADM in the
310 acute setting carries potential in allowing identification of those at low-risk for severe disease, facilitating
311 discharge decisions. Further prospective, multi-centre studies are needed to investigate possible exciting clinical
312 applications of this and other biomarkers.
313

315 **Key Messages**

- 316 • Admission MR-proADM predicts 30-day mortality in SARS-CoV-2 infection
- 317 • Admission MR-proADM predicts critical care requirement in SARS-CoV-2 infection
- 318 • Admission MR-proADM predicts NIV requirement in SARS-CoV-2 infection
- 319 • Admission CRP predicts 30-day mortality, NIV and critical care requirement
- 320 • Admission PCT and White Cell Count do not predict clinical outcomes

321 **Author Contributions** NAM, MY, KG and NC contributed to the study conception and design. Material
322 preparation was performed by TL. Data collection was performed by RW, MM, BB, GV and JL. Analysis was
323 performed by NAM and PP. The first draft of the manuscript was written by NAM. RW, SPK, CT, VGA, KS,
324 KG and NC commented on previous versions of the manuscript. All authors read and approved the final
325 manuscript.

326
327 **Ethical approval** Local Hampshire Hospitals NHS Foundation Trust R&D approval was obtained. HRA
328 Approval was sought who deemed an ethical review was not necessary. HRA Approval was subsequently
329 granted for this project (IRAS project ID: 299130). Anonymised confidential patient information was used
330 under the COVID-19 COPI notice issued by the UK Department of Health and Social Care

331
332 **Conflicts of Interest** Thermofisher provided reagent for measurement of MR-proADM free of charge. PP
333 received payment from Thermofisher and KS has received research grants from Pfizer and Thermofisher.
334 However, neither the payment for PP nor the research grants for KS had any role in study conception or design,
335 the collection, management, analysis, or interpretation of the data, in the preparation, review, or approval of the
336 manuscript, or in the decision to submit the manuscript for publication. There are no non-financial interests.
337 Other authors have no conflicts of interest.

- 338 [1] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
339 Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-8.
- 340 [2] Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular
341 traps in COVID-19. *JCI Insight*. 2020;5(11).
- 342 [3] Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: A New Biomarker for Early
343 Diagnosis of Sepsis in Burned Patients. *J Burn Care Res*. 2017;38(5):290-8.
- 344 [4] Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, et al. The use of mid-
345 regional proadrenomedullin to identify disease severity and treatment response to sepsis - a
346 secondary analysis of a large randomised controlled trial. *Crit Care*. 2018;22(1):79.
- 347 [5] Elke G, Bloos F, Wilson DC, Meybohm P, Group SCCT. Identification of developing multiple
348 organ failure in sepsis patients with low or moderate SOFA scores. *Crit Care*. 2018;22(1):147.
- 349 [6] Legramante JM, Mastropasqua M, Susi B, Porzio O, Mazza M, Miranda Agrippino G, et al.
350 Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia
351 in the Emergency Department compared to clinical severity scores PSI and CURB. *PLoS One*.
352 2017;12(11):e0187702.
- 353 [7] Pereira JM, Azevedo A, Basílio C, Sousa-Dias C, Mergulhão P, Paiva JA. Mid-regional
354 proadrenomedullin: An early marker of response in critically ill patients with severe community-
355 acquired pneumonia? *Rev Port Pneumol (2006)*. 2016;22(6):308-14.
- 356 [8] Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EMS, et
357 al. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary
358 tract infection. *J Infect*. 2018;77(1):18-24.
- 359 [9] van der Starre WE, Zunder SM, Vollaard AM, van Nieuwkoop C, Stalenhoef JE, Delfos NM, et
360 al. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting
361 outcome of febrile urinary tract infection. *Clin Microbiol Infect*. 2014;20(10):1048-54.
- 362 [10] von Haehling S, Filippatos GS, Papassotiropoulos J, Cicoira M, Jankowska EA, Doehner W, et al.
363 Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart
364 failure. *Eur J Heart Fail*. 2010;12(5):484-91.
- 365 [11] Saeed K, Wilson DC, Bloos F, Schuetz P, van der Does Y, Melander O, et al. The early
366 identification of disease progression in patients with suspected infection presenting to the
367 emergency department: a multi-centre derivation and validation study. *Crit Care*. 2019;23(1):40.
- 368 [12] Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox
369 regression. *Am J Epidemiol*. 2007;165(6):710-8.
- 370 [13] Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Moons KG, et al. Minimum sample size for
371 developing a multivariable prediction model: PART II - binary and time-to-event outcomes. *Stat Med*.
372 2019;38(7):1276-96.
- 373 [14] Group RC. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a
374 randomised, controlled, open-label, platform trial. *Lancet*. 2021;397(10274):605-12.
- 375 [15] Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of
376 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020;383(21):2030-40.
- 377 [16] Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a
378 randomised, controlled, open-label, platform trial. *Lancet*. 2020.
- 379 [17] Baldirà J, Ruiz-Rodríguez JC, Wilson DC, Ruiz-Sanmartin A, Cortes A, Chiscano L, et al.
380 Biomarkers and clinical scores to aid the identification of disease severity and intensive care
381 requirement following activation of an in-hospital sepsis code. *Ann Intensive Care*. 2020;10(1):7.
- 382 [18] Gonzalez Del Castillo J, Wilson DC, Clemente-Callejo C, Román F, Bardés-Robles I, Jiménez I,
383 et al. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic
384 administration or intensive care admission. *Crit Care*. 2019;23(1):335.
- 385 [19] Improvement NEaN. Interim Clinical Commissioning Policy: Tocilizumab for critically ill
386 patients with COVID-19 pneumonia (adults)
387 <https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy->

388 [tocilizumab-for-hospitalised-patients-patients-with-covid-19-pneumonia-adults/](#): NHS England and
389 NHS Improvement; 2021 [
390 [20] Improvement NEaN. Interim Clinical Commissioning Policy: Sarilumab for critically ill patients
391 with COVID-19 pneumonia (adults) [https://www.england.nhs.uk/coronavirus/publication/interim-](https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-sarilumab-for-critically-ill-patients-with-covid-19-pneumonia-adults/)
392 [clinical-commissioning-policy-sarilumab-for-critically-ill-patients-with-covid-19-pneumonia-adults/](#):
393 NHS England and NHS Improvement; 2021 [
394 [21] Xie Z, Chen WS, Yin Y, Chan EC, Terai K, Long LM, et al. Adrenomedullin surges are linked to
395 acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol.
396 2018;103(4):749-59.
397